Import from '@/components/mdx'

AOD-9604 Patent Field & Generic Timeline: What Women Need to Know

What Exactly Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to the last 16 amino acids (positions 176-191) of the C-terminus of human growth hormone (hGH). It is sometimes called HGH fragment 176-191. The "AOD" designation stands for anti-obesity drug, a label assigned during early pharmaceutical development by Monash University researchers in Australia who were looking for the fat-metabolizing portion of the GH molecule without the diabetogenic and mitogenic effects of the full hormone.

The core scientific premise is straightforward. Full-length growth hormone does two distinct things: it drives tissue growth and IGF-1 production through the GH receptor, and it promotes fat breakdown through a separate mechanism involving beta-3 adrenergic pathways and regulation of key lipogenic enzymes. Researchers hypothesized that isolating the fragment responsible for the second action would give you fat loss without the downsides of elevated IGF-1 or insulin resistance.

Heffernan et al. (2001) in Endocrinology tested this hypothesis in obese mice and found that AOD-9604 produced significant reductions in body weight and fat mass, stimulated lipolysis in fat cells, and inhibited lipogenesis, all without activating the GH receptor or raising IGF-1 levels. That single animal study remains the most-cited piece of primary evidence for the compound's mechanism.

How the Mechanism Differs From Full GH

Full-length hGH binds the GH receptor, which triggers JAK2-STAT5 signaling and drives IGF-1 production in the liver. High IGF-1 promotes cell proliferation, which is one reason exogenous GH carries cancer-risk concerns. AOD-9604 does not bind the GH receptor at pharmacologically relevant concentrations. Instead, it appears to work through a beta-3 adrenoreceptor-dependent mechanism in adipocytes, promoting the release of free fatty acids from stored triglycerides and suppressing de novo lipogenesis enzymes including fatty acid synthase (FAS).

This distinction matters for women. Women already have a more lipoprotein-lipase-dominant fat storage pattern in the gluteofemoral region compared with men, and the hormonal shifts of perimenopause drive fat redistribution toward visceral depots. A compound that targets adipocyte lipolysis directly, without the IGF-1 elevation that carries breast-tissue proliferation risk, is theoretically appealing for that population. Theoretically. The animal data do not automatically translate.

What the Human Trials Actually Showed

After the promising animal data, Metabolic Pharmaceuticals (an Australian company spun out of Monash University research) ran Phase II and Phase III human trials in the early 2000s under the product name Thinora. The results were disappointing. A Phase III trial registered in Australia failed to show statistically significant weight loss versus placebo in obese adults at the doses tested. Metabolic Pharmaceuticals ultimately did not pursue FDA or TGA approval, and development was abandoned.

Women were included in those trials, but sex-stratified efficacy data were never published in peer-reviewed form, which is consistent with the broader problem of under-reporting of female-specific subgroup results in metabolic drug trials. We do not know whether women respond differently from men, whether cycle phase affects absorption, or whether perimenopausal hormonal status modifies the lipolytic effect. That is an evidence gap, and it should be named as one.

The Patent Field: Why There Is No "Generic" to Wait For

The standard patent-to-generic timeline that consumers follow for small-molecule drugs (brand exclusivity, Paragraph IV challenges, 180-day generic exclusivity, then ANDA approvals) does not apply to AOD-9604. Here is why.

No Reference Listed Drug Exists

A generic drug application (ANDA) under the Hatch-Waxman Act requires a reference listed drug (RLD), meaning an FDA-approved brand-name product against which bioequivalence is demonstrated. Because AOD-9604 was never approved by the FDA, there is no RLD. No company can file an ANDA. There is no generic waiting in the pipeline.

Original Patent Status

Metabolic Pharmaceuticals held composition-of-matter and method-of-use patents covering AOD-9604 and related GH-fragment peptides in the late 1990s and early 2000s. Standard 20-year patent terms from filing dates in roughly 1997-2001 would place expiration between 2017 and 2021. Those patents have expired. No patent extension (like the 5-year Hatch-Waxman extension available for small molecules that delayed FDA approval) was granted, because FDA approval was never obtained.

The practical result: AOD-9604 is now in the public domain from a patent standpoint. Any compounding pharmacy with appropriate equipment, a licensed pharmacist, and a valid prescription can prepare it legally under 503A of the Food, Drug, and Cosmetic Act. This is the current commercial reality.

The 503A Compounding Pathway

Section 503A of the FD&C Act permits licensed pharmacists to compound drugs for individual patients when three conditions are met: a valid patient-specific prescription exists, the drug is not on the FDA's list of drug products that have been withdrawn or removed from the market for safety or effectiveness reasons, and the compound does not appear on FDA's "Demonstrably Difficult to Compound" list.

AOD-9604 does not appear on any FDA withdrawn-drug list and is not on the demonstrably-difficult list. It is currently compoundable under 503A. However, FDA has signaled ongoing scrutiny of peptides broadly, particularly those without approved reference products, and the regulatory status of any given compounded peptide can change if FDA places it on the Category 2 list under its bulk drug substances evaluation process. Women using compounded AOD-9604 should understand that access is not guaranteed to remain open.

The WomanRx Compounded Peptide Access Framework: When evaluating any compounded peptide like AOD-9604, ask four questions before prescribing or ordering: (1) Is there an active FDA bulk-drug-substance evaluation that could restrict compounding within 12-24 months? (2) Does the prescribing clinician have documented clinical rationale in the chart? (3) Has the compounding pharmacy been inspected by the state board of pharmacy in the past 36 months? (4) Is there a plan to monitor both efficacy (DEXA scan, waist circumference) and safety (fasting glucose, lipid panel) at 90 days?

AOD-9604 and the FDA Regulatory Clock

Understanding where AOD-9604 sits on the FDA's regulatory radar helps you anticipate access changes.

The FDA evaluates bulk drug substances proposed for use in compounding under a multi-stage process. Substances land on one of three lists: Category 1 (nominated, under review), Category 2 (not appropriate for compounding), or an affirmative inclusion list (approved for compounding). AOD-9604 has been nominated to the bulk-drug-substances list and has sat in Category 1 review for several years. A Category 2 designation would effectively end legal compounding in the United States.

The FDA's 2023 and 2024 guidance documents on peptide compounding have created real uncertainty. The agency has not moved AOD-9604 to Category 2 as of the date of this article's last review, but the trajectory of FDA peptide policy is toward tighter restrictions, not loosening. Women who begin a course of AOD-9604 may find supply disrupted if FDA acts.

No biosimilar pathway applies here, either. The 351(k) biosimilar route under the Biologics Price Competition and Innovation Act covers large biological molecules (proteins above a certain size threshold) with a reference product. A 16-amino-acid peptide occupies a gray zone in FDA's small-molecule-vs-biologic classification, but because no approved reference product exists for AOD-9604, neither the small-molecule ANDA nor the biologics 351(k) pathway opens a clear generic route.

Mechanism Deep Dive: Why Women's Physiology Makes This Complicated

Hormonal Modulation of Adipocyte Lipolysis

Women's adipose tissue is hormonally regulated in ways that men's is not. Estrogen increases lipoprotein lipase activity in gluteofemoral fat during reproductive years (storing fat there for reproductive energy reserves) and then, as estrogen falls in perimenopause, shifts fat distribution toward visceral depots. Visceral adipocytes are more metabolically active and more lipolysis-responsive to catecholamines than subcutaneous femoral adipocytes.

If AOD-9604 acts through beta-3 adrenergic pathways in adipocytes (as the Heffernan et al. Data suggest), its efficacy might theoretically differ across the menstrual cycle, since estrogen upregulates beta-adrenergic receptor density in adipocytes, and during the luteal phase, progesterone may partly oppose lipolysis. No human study has examined cycle-phase-dependent pharmacodynamics of AOD-9604. This is not a minor gap. It means the 250-300 mcg once-daily dosing used in compounding practices has no cycle-adjusted evidence base for women of reproductive age.

PCOS and Insulin Resistance

Women with polycystic ovary syndrome (PCOS) often have insulin resistance, elevated androgens, and disproportionate visceral fat accumulation. Because AOD-9604 does not appear to affect insulin signaling or the GH/IGF-1 axis at low doses, it is sometimes marketed as a safer alternative to full GH peptides for women with PCOS. This claim is not supported by controlled human data in PCOS populations. The one relevant animal study showed no effect on fasting glucose or insulin in obese mice, which is reassuring but not definitive.

Women with PCOS who are using metformin or a GLP-1 receptor agonist (like semaglutide) alongside AOD-9604 should be aware that no drug-drug interaction studies exist for these combinations. The theoretical concern is additive hypoglycemia risk, though it is low given AOD-9604's presumed mechanism.

Perimenopausal Women: The Most Likely User

In clinical practice, perimenopausal women aged 40-55 are the most common group seeking AOD-9604 through compounding channels. They face visceral fat gain driven by declining estrogen, often have co-existing insulin resistance, and may already be using menopausal hormone therapy (MHT). The interaction between MHT (particularly estradiol) and AOD-9604's lipolytic mechanism has not been studied. Oral estrogen increases growth hormone binding protein levels and may theoretically alter GH-fragment pharmacokinetics, but no pharmacokinetic data in MHT users exist.

The Menopause Society's 2023 position statement on menopause and weight recommends lifestyle modification and, where appropriate, FDA-approved pharmacological therapies as first-line approaches to menopausal weight gain. AOD-9604 is not included in those recommendations, and the statement does not address peptide compounding.

Pregnancy, Lactation, and Contraception

AOD-9604 is contraindicated in pregnancy. There are no human pregnancy data. Animal reproductive toxicology studies for this specific peptide have not been published in peer-reviewed literature. Given that any exogenous peptide with potential effects on adipocyte function and metabolic signaling carries unknown fetal risk, and given the complete absence of safety data, no clinician should prescribe AOD-9604 to a pregnant woman.

If you are trying to conceive, discontinue AOD-9604 before attempting pregnancy. The peptide's half-life is short (estimated under 30 minutes based on GH-fragment pharmacokinetics), so washout is rapid, but the instruction to stop should be clear.

Lactation: No data exist on AOD-9604 transfer into breast milk. Peptides of this size are generally degraded in the infant's gastrointestinal tract if ingested orally, but subcutaneous administration by the mother bypasses that protection at the maternal level, and some transfer via milk cannot be excluded. The standard recommendation from LactMed principles would be to avoid AOD-9604 while breastfeeding until transfer data are available. There are none.

Contraception: AOD-9604 is not known to be teratogenic in the way that classic teratogens like isotretinoin are, but the absence of any reproductive safety data means it should be treated with appropriate caution. Women of reproductive age using AOD-9604 should use reliable contraception during a course of treatment and for at least one full cycle after stopping, pending any future reproductive toxicology data.

Who This Is Right For (and Who It Is Not)

Potentially Appropriate Candidates

Women who may be reasonable candidates for clinician-supervised AOD-9604 use include those who:

• Are postmenopausal and not pregnant or breastfeeding, with a primary goal of visceral fat reduction as part of a comprehensive metabolic plan
• Have normal fasting glucose and no personal history of pituitary or growth-related tumors
• Understand that they are using a compounded peptide with no FDA-approved indication and limited human trial data
• Have access to a prescribing clinician who will monitor metabolic markers at baseline and at 90 days
• Are not using full-length GH, IGF-1-stimulating peptides, or other lipolytic agents simultaneously

Not Appropriate For

AOD-9604 is not appropriate for women who are:

• Pregnant, trying to conceive, or breastfeeding (as detailed above)
• Under age 18 (no pediatric data)
• Diagnosed with or at elevated risk for hormone-sensitive cancers, including breast cancer, given the complete absence of long-term oncologic safety data
• Currently experiencing poorly controlled diabetes (no data in this population)
• Relying on the peptide as a substitute for FDA-approved obesity pharmacotherapy when that therapy is indicated and available

Women with PCOS, perimenopause-driven weight gain, or thyroid-related metabolic changes deserve honest conversations about the evidence base for AOD-9604 compared with drugs that have completed Phase III trials in women.

Dosing in Clinical Practice: What Compounders Are Using

Because no FDA-approved labeling exists, the dosing figures circulating in clinical practice come from the abandoned Metabolic Pharmaceuticals trials and from prescriber convention rather than from a regulatory document.

The most commonly prescribed compounded dose is 250-300 mcg subcutaneously once daily, typically injected in the morning in a fasted state. Some protocols use 500 mcg per day split into two injections. The injectable solution is typically prepared in bacteriostatic water at concentrations of 5 mg/mL.

No published pharmacokinetic study in women exists to confirm whether body composition, hormonal status, or cycle phase alters absorption, distribution, or elimination of the peptide. A woman with 35% body fat may have very different subcutaneous tissue characteristics than a male participant in an animal-derived dosing model.

The absence of sex-specific pharmacokinetic data is a direct consequence of the drug never having completed FDA approval. It means that every dose a woman receives through a compounding pharmacy is, in a very real sense, experimental.

The Realistic Timeline: Will AOD-9604 Ever Get FDA Approval?

No pharmaceutical company has an active IND (investigational new drug application) for AOD-9604 in the United States for the adipose indication as of this writing. The original Phase III failure, combined with the absence of patent protection that would justify new drug development investment, makes re-filing commercially unattractive.

A sponsor would need to run new Phase III trials meeting modern FDA standards, including at minimum 12 months of treatment data, cardiovascular safety data (since the FDA's 2012 guidance on obesity drugs requires cardiovascular outcome data or a pre-approval cardiovascular safety assessment), and sex-disaggregated efficacy analyses. The cost of that program, in the tens of millions of dollars, cannot be recovered through a drug that any compounding pharmacy can make. The commercial incentive to pursue approval does not exist.

This means the "generic timeline" question has a definitive answer: there will be no FDA-approved generic AOD-9604 in any foreseeable regulatory timeframe. Women who use this compound will access it through compounding for the foreseeable future, with all the quality, consistency, and regulatory uncertainty that entails.

The one scenario that could change this: if a next-generation GH fragment analog with improved efficacy data were patented and developed by a pharmaceutical company, AOD-9604 itself might gain new research attention as a comparator. That is speculative. No such analog is in late-stage development as of 2025.